Reviva Pharmaceutcls Hldgs Inc Financials

RVPH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Reviva Pharmaceutcls Hldgs Inc (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RVPH FY2025 2026-05-13

Reviva operates as a cash-funded development program, with capital raises replenishing a balance sheet that operations still drain.

From FY2023 to FY2025, financing inflows of $82.4M nearly matched operating cash burn of $86.5M, so the business has functioned more like a funded research platform than a self-supporting enterprise. FY2025 cash on hand of $14.4M covered only 0.6x that year's operating outflow, even after R&D spending was cut sharply from FY2024.

The clearest improvement is in balance-sheet posture: total liabilities fell to $7.3M in FY2025 from $14.7M in FY2024, which rebuilt equity and reduced how much of the asset base is spoken for by obligations. With the current ratio at 2.1x after sitting near 1.0x a year earlier, near-term liquidity looks less constrained than the loss figures alone imply.

The losses are still mostly an operating choice, not a financing burden: FY2025 interest expense was only $13K against an operating loss of $20.2M, so debt service is not what is driving the deficit. In both FY2024 and FY2025, operating cash outflow exceeded net loss, which means the cash requirement remained heavier than the accounting loss line suggests.

Financial Health Signals

Financial Profile 20/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Reviva Pharmaceutcls Hldgs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Reviva Pharmaceutcls Hldgs Inc carries a low D/E ratio of 0.84, meaning only $0.84 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Reviva Pharmaceutcls Hldgs Inc's current ratio of 2.08 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Reviva Pharmaceutcls Hldgs Inc generates a -229.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -3682.0% the prior year.

Piotroski F-Score Weak

2/9

Reviva Pharmaceutcls Hldgs Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.24x

For every $1 of reported earnings, Reviva Pharmaceutcls Hldgs Inc generates $1.24 in operating cash flow (-$24.6M OCF vs -$19.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1507.2x

Reviva Pharmaceutcls Hldgs Inc earns $-1507.2 in operating income for every $1 of interest expense (-$20.2M vs $13K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$19.9M

YoY+33.6%

Reviva Pharmaceutcls Hldgs Inc reported -$19.9M in net income in fiscal year 2025. This represents an increase of 33.6% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$14.4M

YoY+7.1%

5Y CAGR+10.5%

Reviva Pharmaceutcls Hldgs Inc held $14.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+148.9%

Reviva Pharmaceutcls Hldgs Inc had 6M shares outstanding in fiscal year 2025. This represents an increase of 148.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-229.7%

YoY+3452.3pp

5Y CAGR-160.5pp

Reviva Pharmaceutcls Hldgs Inc's ROE was -229.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3452.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.7M

YoY-48.9%

5Y CAGR+108.8%

Reviva Pharmaceutcls Hldgs Inc invested $11.7M in research and development in fiscal year 2025. This represents a decrease of 48.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RVPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.7M-48.9%	$22.9M-27.1%	$31.4M+37.4%	$22.9M+371.4%	$4.9M+1543.8%	$295K
SG&A Expenses	$8.5M+7.6%	$7.9M-2.4%	$8.1M+50.9%	$5.4M+2.0%	$5.3M+145.5%	$2.1M
Operating Income	-$20.2M+34.4%	-$30.8M+22.0%	-$39.5M-39.9%	-$28.2M-179.4%	-$10.1M-315.0%	-$2.4M
Interest Expense	$13K-27.5%	$18K-45.2%	$34K	N/A	$0-100.0%	$1.5M
Income Tax	$19K-3.2%	$20K+15.1%	$17K-18.4%	$21K+246.1%	$6K+650.5%	$800
Net Income	-$19.9M+33.6%	-$29.9M+23.8%	-$39.3M-38.9%	-$28.3M-231.6%	-$8.5M-125.2%	-$3.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.4M	N/A	$2.1M-42.8%	$3.7M-9.5%	$4.1M	N/A	$6.9M+22.8%	$5.6M
SG&A Expenses	$1.8M	N/A	$1.9M-19.2%	$2.3M-3.2%	$2.4M	N/A	$1.6M-37.0%	$2.5M
Operating Income	-$3.3M	N/A	-$4.0M+33.6%	-$6.1M+7.1%	-$6.5M	N/A	-$8.5M-4.1%	-$8.1M
Interest Expense	$7K	N/A	$3K-45.7%	$5K-58.7%	$12K	N/A	$5K-0.1%	$5K
Income Tax	$3K	N/A	$3K-64.3%	$8K+52.6%	$5K	N/A	$0-100.0%	$7K
Net Income	-$3.2M	N/A	-$4.0M+33.7%	-$6.1M+5.9%	-$6.4M	N/A	-$8.4M-6.4%	-$7.9M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.9M+2.7%	$15.5M-34.6%	$23.7M+25.2%	$18.9M-39.7%	$31.4M+258.4%	$8.8M
Current Assets	$15.1M+2.9%	$14.7M-38.0%	$23.7M	N/A	N/A	$44K
Cash & Equivalents	$14.4M+7.1%	$13.5M-42.3%	$23.4M+26.2%	$18.5M-37.6%	$29.7M+238.9%	$8.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.3M-50.5%	$14.7M-18.3%	$18.0M+70.8%	$10.5M+287.5%	$2.7M-17.6%	$3.3M
Current Liabilities	$7.3M-50.2%	$14.6M-15.0%	$17.2M+72.4%	$10.0M+324.9%	$2.3M+75.9%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.6M+964.2%	$813K-85.8%	$5.7M-31.9%	$8.4M-70.7%	$28.7M+424.8%	$5.5M
Retained Earnings	-$184.1M-12.1%	-$164.3M-22.3%	-$134.4M-41.3%	-$95.1M-42.3%	-$66.8M-14.6%	-$58.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$23.6M+48.0%	$15.9M+11.1%	$14.3M+23.2%	$11.6M+64.4%	$7.1M-54.4%	$15.5M+103.2%	$7.6M-5.3%	$8.1M
Current Assets	$23.6M+56.0%	$15.1M+11.8%	$13.5M+24.9%	$10.8M+72.8%	$6.3M-57.4%	$14.7M+115.6%	$6.8M-5.8%	$7.2M
Cash & Equivalents	$22.2M+53.7%	$14.4M+9.5%	$13.2M+27.2%	$10.4M+95.9%	$5.3M-60.8%	$13.5M+142.4%	$5.6M-10.0%	$6.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M-15.9%	$7.3M-25.6%	$9.8M-19.1%	$12.1M+4.8%	$11.5M-21.5%	$14.7M-16.6%	$17.6M+25.0%	$14.1M
Current Liabilities	$6.1M-15.9%	$7.3M-25.3%	$9.7M-19.4%	$12.1M+4.9%	$11.5M-21.2%	$14.6M-16.7%	$17.5M+25.7%	$13.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$17.4M+101.7%	$8.6M+90.1%	$4.5M+1090.9%	-$459K+89.7%	-$4.5M-648.9%	$813K+108.1%	-$10.0M-65.2%	-$6.0M
Retained Earnings	-$187.3M-1.7%	-$184.1M-1.9%	-$180.8M-2.3%	-$176.8M-3.5%	-$170.7M-3.9%	-$164.3M-4.0%	-$158.0M-5.6%	-$149.6M

RVPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$24.6M+26.7%	-$33.5M-18.4%	-$28.3M-49.4%	-$19.0M-77.7%	-$10.7M-162.3%	-$4.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$25.6M+8.1%	$23.7M-28.7%	$33.2M+325.7%	$7.8M-75.3%	$31.6M+146.3%	$12.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.8M+34.4%	-$5.8M-3.7%	-$5.6M-11.5%	-$5.0M+38.8%	-$8.2M+10.0%	-$9.1M-114.6%	-$4.2M+50.0%	-$8.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$11.6M+63.8%	$7.1M-16.1%	$8.4M-16.6%	$10.1M+138630.0%	$7K-100.0%	$17.0M+369.8%	$3.6M+35.1%	$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-229.7%+3452.3pp	-3682.0%-2995.5pp	-686.5%-349.9pp	-336.7%-307.0pp	-29.7%+39.5pp	-69.2%
Return on Assets	-124.8%+68.2pp	-193.0%-27.3pp	-165.7%-16.3pp	-149.3%-122.2pp	-27.1%+16.0pp	-43.2%
Current Ratio	2.08+1.1	1.01-0.4	1.38	N/A	N/A	0.03
Debt-to-Equity	0.84-17.2	18.08+14.9	3.14+1.9	1.25+1.2	0.09-0.5	0.60
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-18.3%	N/A	-88.1%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-13.6%	N/A	-28.0%+24.1pp	-52.0%+38.9pp	-90.9%	N/A	-109.7%-12.0pp	-97.6%
Current Ratio	3.85+1.8	2.08+0.7	1.39+0.5	0.90+0.4	0.54-0.5	1.01+0.6	0.39-0.1	0.52
Debt-to-Equity	0.35-0.5	0.84-1.3	2.15+28.5	-26.34-23.8	-2.59-20.7	18.08+19.8	-1.76+0.6	-2.33
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tenax Therapeutics Inc TENX

$308.2M

Neuphoria Therapeutics Inc NEUP

$25.5M

LakeShore Biopharma Co., Ltd LSB

$25.8M

OnKure Therapeutics OKUR

$124.4M

Frequently Asked Questions

Is Reviva Pharmaceutcls Hldgs Inc profitable?

No, Reviva Pharmaceutcls Hldgs Inc (RVPH) reported a net income of -$19.9M in fiscal year 2025.

What is Reviva Pharmaceutcls Hldgs Inc's return on equity (ROE)?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has a return on equity of -229.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Reviva Pharmaceutcls Hldgs Inc's operating cash flow?

Reviva Pharmaceutcls Hldgs Inc (RVPH) generated -$24.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Reviva Pharmaceutcls Hldgs Inc's total assets?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Reviva Pharmaceutcls Hldgs Inc spend on research and development?

Reviva Pharmaceutcls Hldgs Inc (RVPH) invested $11.7M in research and development during fiscal year 2025.

How many shares does Reviva Pharmaceutcls Hldgs Inc have outstanding?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had 6M shares outstanding as of fiscal year 2025.

What is Reviva Pharmaceutcls Hldgs Inc's current ratio?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.

What is Reviva Pharmaceutcls Hldgs Inc's debt-to-equity ratio?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a debt-to-equity ratio of 0.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Reviva Pharmaceutcls Hldgs Inc's return on assets (ROA)?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had a return on assets of -124.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Reviva Pharmaceutcls Hldgs Inc's cash runway?

Based on fiscal year 2025 data, Reviva Pharmaceutcls Hldgs Inc (RVPH) had $14.4M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Reviva Pharmaceutcls Hldgs Inc's Piotroski F-Score?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Reviva Pharmaceutcls Hldgs Inc's earnings high quality?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an earnings quality ratio of 1.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Reviva Pharmaceutcls Hldgs Inc cover its interest payments?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an interest coverage ratio of -1507.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Reviva Pharmaceutcls Hldgs Inc?

Reviva Pharmaceutcls Hldgs Inc (RVPH) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.